Amprenavir review

Amprenavir was developed by a U.S manufacturer GlaxoSmithKline. This drug was first approved by the U.S. Food and Drug Association (FDA) in 1999 to be used for treating HIV infections that is considered to be impossible with previous medical technology.

Amprenavir is defined as a protease inhibitor that was approved in 1999. It is an antiretroviral drug or ARV for treating people with HIV infection. Studies show that people with HIV over 4 years of age can make use of this drug. The medication is commonly used for people who have a high viral load with low levels of CD4 Cell Counts. This method is used to keep HIV patients healthy with every treatment.

The amprenavir capsule is orally ingested with a full glass of water. Adults are prescribed to take 1,200mg twice a day. This was first tested using the 150mg capsules that are no longer manufactured today. Considering that amprenavir capsule is no longer manufactured; people with HIV infection can take in the drug fosamprevanir as substitute.

Today, amprenavir is approved for use along with ritonavir -- another protease inhibitor drug. Dosage may include one of the following depending upon the advice of your doctor or physician:

1. 100mg of ritonavir along with 600mg or 4 capsules of amprenavir; twice a day; or
2. 200mg of ritonavir (2 caps) along with 1,200mg (8 caps) of amprenavir; once a day.

Common side effects associated with amprenavir include diarrhea, nausea, vomiting, numbness around the mouth, rashes, and stomach pains. A small population of the patients taking in amprenavir suffers from serious skin reactions, such as the Stevens-Johnson syndrome or other allergic reactions to the medication. Doctors prescribe over-the-counter medications to control some of these side effects.

People with allergic reaction to sulfa drugs might want to refrain from using amprenavir or seek the advice of a doctor or physician if you plan to proceed with the treatment. Considering that that amprenavir is a protease inhibitor, there were no records of it having problems with people suffering from high-cholesterol levels unlike other drugs in the same family.

Liquid-based amprevanir contains glycol that may cause some problems with infants under 4 years old, people suffering from kidney or liver problems, pregnant women, or those under specific medications.

There is a possibility for amprenavir to react with other medications or herbal supplements. Both drugs in the system might trigger an overdose that could prove fatal to the patient or an underdose that will render the treatment useless.

In most cases, other ARV drugs are said to interact adversely with amprenavir. Patients currently treated with tuberculosis drugs should avoid using the said medication. Drugs to treat headaches and migraines, as well as those used for erectile dysfunctions and control heart rhythms should be avoided when being treated with amprenavir or vice versa.

As with other protease inhibitors, patients who are planning a treatment using amprenavir must consult their doctor for a thorough physical and medical examination to avoid risks, as well as following the prescribed dosage to avoid contraindications and fatal reactions.

Amprenavir has the following structural formula:

Chemical structure of amprenavir

• Molecular formula of amprenavir is C25H35N3O6S
• Chemical IUPAC Name is tetrahydrofuran-3-yl[3-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]- 1-benzyl-2-hydroxy-propyl]aminomethanoate
• Molecular weight is 505.628 g/mol
Amprenavir available : 50mg capsules

Brand name(s): Agenerase, Lexiva

  Your Amprenavir review